Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

An RNA vaccine drives expansion and efficacy of claudin-CAR-T cells against solid tumors
Katharina Reinhard, Benjamin Rengstl, Petra Oehm, et al.
Science (2020) Vol. 367, Iss. 6476, pp. 446-453
Open Access | Times Cited: 388

Showing 1-25 of 388 citing articles:

Lipid nanoparticles for mRNA delivery
Xucheng Hou, Tal Zaks, Róbert Langer, et al.
Nature Reviews Materials (2021) Vol. 6, Iss. 12, pp. 1078-1094
Open Access | Times Cited: 2183
Therapeutic cancer vaccines
Mansi Saxena, Sjoerd H. van der Burg, Cornelis J.M. Melief, et al.
Nature reviews. Cancer (2021) Vol. 21, Iss. 6, pp. 360-378
Closed Access | Times Cited: 1076
Drug delivery systems for RNA therapeutics
Kalina Paunovska, David Loughrey, James E. Dahlman
Nature Reviews Genetics (2022) Vol. 23, Iss. 5, pp. 265-280
Open Access | Times Cited: 808
An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma
Uğur Şahin, Petra Oehm, Evelyna Derhovanessian, et al.
Nature (2020) Vol. 585, Iss. 7823, pp. 107-112
Closed Access | Times Cited: 749
Clinical implications of T cell exhaustion for cancer immunotherapy
Andrew Chow, Karlo Perica, Christopher A. Klebanoff, et al.
Nature Reviews Clinical Oncology (2022) Vol. 19, Iss. 12, pp. 775-790
Open Access | Times Cited: 492
Cancer vaccines as promising immuno-therapeutics: platforms and current progress
Jian Liu, Minyang Fu, Manni Wang, et al.
Journal of Hematology & Oncology (2022) Vol. 15, Iss. 1
Open Access | Times Cited: 469
mRNA-based therapeutics: powerful and versatile tools to combat diseases
Shugang Qin, Xiaoshan Tang, Yu‐Ting Chen, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 403
Lipids and Lipid Derivatives for RNA Delivery
Yuebao Zhang, Changzhen Sun, Chang Wang, et al.
Chemical Reviews (2021) Vol. 121, Iss. 20, pp. 12181-12277
Open Access | Times Cited: 389
The cancer-immunity cycle: Indication, genotype, and immunotype
Ira Mellman, Daniel S. Chen, Thomas Powles, et al.
Immunity (2023) Vol. 56, Iss. 10, pp. 2188-2205
Open Access | Times Cited: 345
The challenge and prospect of mRNA therapeutics landscape
Yuhua Weng, Chunhui Li, Tongren Yang, et al.
Biotechnology Advances (2020) Vol. 40, pp. 107534-107534
Closed Access | Times Cited: 315
CAR T Cell Therapy for Solid Tumors: Bright Future or Dark Reality?
Jessica Wagner, Elizabeth Wickman, Christopher DeRenzo, et al.
Molecular Therapy (2020) Vol. 28, Iss. 11, pp. 2320-2339
Open Access | Times Cited: 293
Passive, active and endogenous organ-targeted lipid and polymer nanoparticles for delivery of genetic drugs
Sean A. Dilliard, Daniel J. Siegwart
Nature Reviews Materials (2023) Vol. 8, Iss. 4, pp. 282-300
Open Access | Times Cited: 293
mRNA Vaccine Era—Mechanisms, Drug Platform and Clinical Prospection
Shuqin Xu, Kunpeng Yang, Rose Li, et al.
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 18, pp. 6582-6582
Open Access | Times Cited: 273
mRNA therapeutics in cancer immunotherapy
Jan D. Beck, Daniel Reidenbach, Nadja Salomon, et al.
Molecular Cancer (2021) Vol. 20, Iss. 1
Open Access | Times Cited: 273
Nanomaterials for T-cell cancer immunotherapy
Ningqiang Gong, Neil C. Sheppard, Margaret M. Billingsley, et al.
Nature Nanotechnology (2021) Vol. 16, Iss. 1, pp. 25-36
Closed Access | Times Cited: 244
CAR T therapy beyond cancer: the evolution of a living drug
Daniel Baker, Zoltàn Arany, Joseph A. Baur, et al.
Nature (2023) Vol. 619, Iss. 7971, pp. 707-715
Closed Access | Times Cited: 233
Engineered cellular immunotherapies in cancer and beyond
Amanda Finck, Tatiana Blanchard, Christopher P. Roselle, et al.
Nature Medicine (2022) Vol. 28, Iss. 4, pp. 678-689
Open Access | Times Cited: 208
Algorithm for optimized mRNA design improves stability and immunogenicity
He Zhang, Liang Zhang, Ang Lin, et al.
Nature (2023) Vol. 621, Iss. 7978, pp. 396-403
Open Access | Times Cited: 198
Current status and perspective of CAR-T and CAR-NK cell therapy trials in Germany
Nawid Albinger, Jessica Hartmann, Evelyn Ullrich
Gene Therapy (2021) Vol. 28, Iss. 9, pp. 513-527
Open Access | Times Cited: 196
CAR T cell therapy for patients with solid tumours: key lessons to learn and unlearn
Steven Μ. Albelda
Nature Reviews Clinical Oncology (2023) Vol. 21, Iss. 1, pp. 47-66
Closed Access | Times Cited: 173
Towards new horizons: characterization, classification and implications of the tumour antigenic repertoire
Sebastian P. Haen, Markus Löffler, Hans‐Georg Rammensee, et al.
Nature Reviews Clinical Oncology (2020) Vol. 17, Iss. 10, pp. 595-610
Open Access | Times Cited: 172
Reactivation of the tumor suppressor PTEN by mRNA nanoparticles enhances antitumor immunity in preclinical models
Yao‐Xin Lin, Yi Wang, Jianxun Ding, et al.
Science Translational Medicine (2021) Vol. 13, Iss. 599
Open Access | Times Cited: 162
Active transcytosis and new opportunities for cancer nanomedicine
Subhendu Pandit, Debapriya Dutta, Shuming Nie
Nature Materials (2020) Vol. 19, Iss. 5, pp. 478-480
Closed Access | Times Cited: 152
Current Immunotherapies for Glioblastoma Multiforme
Boyuan Huang, Xuesong Li, Yuntao Li, et al.
Frontiers in Immunology (2021) Vol. 11
Open Access | Times Cited: 132
Next-Generation CAR T-cell Therapies
Regina M. Young, Nils W. Engel, Uğur Uslu, et al.
Cancer Discovery (2022) Vol. 12, Iss. 7, pp. 1625-1633
Open Access | Times Cited: 123
Page 1 - Next Page

Scroll to top